VRDN Viridian Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VRDN

Price (delayed)

$21.43

Market cap

$2.43B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.39

Enterprise value

$2.62B

?
Relative Growth: Rel. Growth: 73
Relative Strength: Rel. Strength: 48
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 30

Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the ...

Highlights
VRDN's quick ratio has surged by 55% year-on-year and by 13% since the previous quarter
The equity rose by 29% YoY and by 4.1% QoQ
The net income has contracted by 12% YoY and by 7% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.miragen.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of VRDN

VRDN stock price

How has the Viridian Therapeutics stock price performed over time
Intraday
-3.12%
1 week
-4.5%
1 month
-11.77%
1 year
9.56%
YTD
-31.14%
QTD
16.66%

Financial performance

How have Viridian Therapeutics's revenue and profit performed over time
Revenue
$71.13M
Gross profit
$71.13M
Operating income
-$405.2M
Net income
-$386.97M
Gross margin
100%
Net margin
-544.1%
The operating margin has soared by 100% YoY but it has decreased by 4.7% QoQ
Viridian Therapeutics's net margin has surged by 100% YoY but it has decreased by 7% QoQ
The net income has contracted by 12% YoY and by 7% from the previous quarter
The operating income has declined by 9% year-on-year and by 5% since the previous quarter

Price vs fundamentals

How does VRDN's price correlate with its fundamentals

Growth

What is Viridian Therapeutics's growth rate over time

Valuation

What is Viridian Therapeutics stock price valuation
P/E
N/A
P/B
3.34
P/S
32.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
36.82
Viridian Therapeutics's EPS has increased by 4.8% YoY
The price to book (P/B) is 38% more than the 5-year quarterly average of 2.5
The equity rose by 29% YoY and by 4.1% QoQ
The P/S is 98% less than the 5-year quarterly average of 1573.3 but 13% more than the last 4 quarters average of 29.6

Efficiency

How efficient is Viridian Therapeutics business performance
Viridian Therapeutics's return on sales has surged by 100% YoY but it has decreased by 5% QoQ
Viridian Therapeutics's return on invested capital has increased by 23% QoQ and by 21% YoY
The company's return on equity fell by 11% YoY
The return on assets rose by 9% since the previous quarter and by 8% year-on-year

Dividends

What is VRDN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VRDN.

Financial health

How did Viridian Therapeutics financials performed over time
Viridian Therapeutics's total assets is 152% higher than its total liabilities
The total liabilities has soared by 184% QoQ
Viridian Therapeutics's total assets has surged by 88% YoY and by 39% QoQ
Viridian Therapeutics's debt is 46% lower than its equity
The equity rose by 29% YoY and by 4.1% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.